Class: Colony-stimulating factor
- Injection 300 mcg/mL
- Injection 300 mcg per 0.5 mL
- Injection, prefilled SingleJect syringes 300 mcg per 0.5 mL
- Injection, prefilled SingleJect syringes 480 mcg per 0.8 mL
Stimulates neutrophil production within bone marrow.
C max is 4 to 49 ng/mL (subcutaneous); T max is 2 to 8 h (subcutaneous).
Vd is about 150 mL/kg.
The half-life is about 3.5 h and Cl is 0.5 to 0.7 mL/min/kg.
Indications and Usage
Cancer patients receiving myelosuppressive chemotherapy; cancer patients with acute myeloid leukemia receiving induction or consolidation chemotherapy; cancer patients receiving bone marrow transplant; patients with severe chronic neutropenia; peripheral blood progenitor cell (PBPC) collection and therapy in cancer patients.
Treatment of graft failure after bone marrow transplantation; neutropenia associated with myelodysplastic syndrome; hairy cell leukemia; aplastic anemia; AIDS; zidovudine- and other drug-induced neutropenia.
Hypersensitivity to Escherichia coli –derived proteins, filgrastim, or any component of the product.
Dosage and AdministrationBone Marrow Transplant
IV/Subcutaneous 10 mcg/kg/day as an IV infusion of 4 or 24 h or as a continuous 24-h subcutaneous infusion. Administer first dose at least 24 h after cytotoxic chemotherapy and at least 24 h after bone marrow infusion.Dose adjustments
When absolute neutrophil count (ANC) is more than 1,000/mm 3 for 3 consecutive days, reduce dosage to 5 mcg/kg/day. Then if ANC remains more than 1,000/mm 3 for 3 more consecutive days, discontinue therapy. Then if ANC decreases to less than 1,000/mm 3 resume 5 mcg/kg/day; if ANC decreases to less than 1,000/mm 3 at any time during 5 mcg/kg/day administration, increase dosage to 10 mcg/kg/day and follow the above dosage adjustment steps.Myelosuppressive Chemotherapy
IV/Subcutaneous Administer no earlier than 24 h after cytotoxic chemotherapy. 5 mcg/kg/day as single daily injection by subcutaneous bolus, by short (15 to 30 min) IV infusion, or by continuous subcutaneous or IV infusion daily for up to 2 wk until ANC reaches 10,000/mm 3 ; may increase in increments of 5 mcg/kg for each chemotherapy cycle.Discontinuation
Therapy should be continued following chemotherapy until the postnadir ANC reaches 10,000/mm 3 . Discontinue if the ANC surpasses 10,000/mm 3 .Severe Chronic Neutropenia
Congenital neutropenia Starting dose
6 mcg/kg subcutaneously twice daily.Idiopathic or Cyclic Neutropenia Starting dose
5 mcg/kg as a single subcutaneous injection once daily.Dose adjustments
Chronic daily administration is required to maintain clinical benefit. Do not use ANC as the sole indication of efficacy. Individually adjust the dose based on the patient's clinical course and ANC.PBPC Collection/Therapy
Subcutaneous 10 mcg/kg/day as bolus subcutaneous injection or continuous infusion; start 4 days before first leukapheresis and continue until last leukapheresis.
- Do not give filgrastim 24 h before or 24 h after cytotoxic chemotherapy.
- For subcutaneous or IV administration only. Not for intradermal, IM, or intra-arterial administration.
- May dilute in dextrose 5% injection to concentration between 5 and 15 mcg/mL; protect from absorption to plastic materials by adding albumin (human) to final concentration of 2 mg/mL. Dilution to final concentration of less than 5 mcg/mL is not recommended. Do not dilute filgrastim with saline.
- Use only 1 dose per vial or prefilled syringe. Do not reenter vials. Discard unused portions; do not save unused portions for later use.
- Do not administer if particulate matter, cloudiness, or discoloration noted.
- Prefilled Syringe
- After administration, activate the UltraSafe needle guard by placing hands behind the needle, grasp the guard with 1 hand and slide the guard forward until needle is completely covered and the guard clicks into place.
Store vials and prefilled syringes in refrigerator (36° to 46°F). Avoid shaking. May allow injection to reach room temperature for a max of 24 h; discard any vial or syringe left at room temperature for more than 24 h.
Drugs that may potentiate the release of neutrophils, such as lithium, should be used with caution. Use with caution in conjunction with other drugs known to lower the platelet count.
Precipitate may form if diluted with saline.
Laboratory Test Interactions
None well documented.
Chest pain (5%); hypertension, hypotension (4%); cardiac events (eg, MI, arrhythmias) (3%).
Fatigue (11%); headache (7%); generalized weakness (4%).
Alopecia (18%); petechiae (17%); rash (12%); cutaneous vasculitis; exacerbation of preexisting skin disorders (eg, psoriasis).
Epistaxis (15%); sore throat (4%).
Nausea/vomiting (57%); diarrhea (14%); mucositis (12%); anorexia (9%); stomatitis, constipation (5%); peritonitis (2%).
Hematuria/proteinuria; renal insufficiency.
Increased neutrophil count (100%); decreased platelet counts (97%); mild to moderate anemia (65%); splenomegaly (30%); increased WBC (12%); severe hemorrhage (7%); thrombocytopenia (4%); acute myeloid leukemia, myelodysplastic syndrome (postmarketing [2% annually]); capillary leak syndrome.
Reversible elevations is alkaline phosphatase, lactate dehydrogenase, uric acid (27% to 58%).
Musculoskeletal symptoms (44%); medullary bone pain, mild to moderate bone pain (33%); skeletal pain (22%); arthralgia; osteoporosis.
Dyspnea (9%); cough (6%).
Neutropenic fever (13%); fever (12%); transfusion reactions (10%); pain (2%); injection-site reaction.
MonitorBone marrow transplant
Obtain CBC and platelet count at least 3 times/wk following marrow transplantation.Myelosuppressive chemotherapy
Obtain CBC, WBC, and platelet count prior to chemotherapy and 2 times/wk during filgrastim therapy.Severe chronic neutropenia
Obtain CBC with differential and platelet count 2 times/wk during first 4 wk of filgrastim therapy, and during the 2 wk following any dose adjustment; once stable, obtain once monthly for first year then at least quarterly thereafter. Perform bone marrow and cytogenetic evaluations annually in patients with congenital neutropenia.PBPC collection/therapy
Obtain neutrophil count after 4 days of filgrastim. Consider dose modification if WBC count greater than 100,000/mm 3 .
Category C .
Safety and efficacy in neonates and patients with autoimmune neutropenia of infancy not established.
Following myelosuppressive chemotherapy, no overall differences in safety and efficacy have been observed between subjects 65 yr of age and older compared with younger subjects. For other approved indications, data are insufficient to make a comparison.
Adult Respiratory Distress Syndrome
Has been reported in neutropenic patients with sepsis.
Allergic-type reactions on initial or subsequent treatment have been reported rarely; generally, these have been characterized by systemic symptoms involving at least 2 body systems, most often skin (eg, rash), respiratory, and cardiovascular.
Bone marrow transplant
Do not administer filgrastim until at least 24 h after cytotoxic chemotherapy and at least 24 h after bone marrow infusion.
MI and arrhythmias have been reported. Use with caution in patients with preexisting cardiac conditions.
Chemotherapy and radiation therapy
Do not use filgrastim in the period 24 h before through 24 h after administration of cytotoxic chemotherapy.
WBC counts of 100,000/mm 3 have been observed in about 2% of patients treated with filgrastim 5 mcg/kg/day. There are no reports of adverse events associated with this degree of leukocytosis; however, regular CBC monitoring is recommended.Premature discontinuation
A transient increase in neutrophil counts is typically seen 1 to 2 days after the start of therapy. For a sustained therapeutic response, therapy should be continued after chemotherapy until the postnadir ANC reaches 10,000/mm 3 . Therefore, premature discontinuation of therapy, prior to the time of recovery from the expected neutrophil nadir, generally is not recommended.
Severe chronic neutropenia
Confirm diagnosis before initiating therapy.
Sickle cell disease
Use with caution; may cause sickle cell crisis.
Has been reported rarely. Evaluate patients reporting left upper abdominal and/or shoulder tip pain for enlarged spleen or splenic rupture.
Filgrastim is a growth factor; the possibility that filgrastim can act as a growth factor for any tumor type cannot be excluded.
- Advise patient or caregiver to read the patient information leaflet before starting therapy and with each refill.
- Ensure patient or caregiver who is administering filgrastim understands how to store, prepare, and administer the dose, and dispose of used equipment and supplies. The first injection should be performed under the supervision of a qualified health care provider.
- Advise patient or caregiver to inject filgrastim at the same time each day.
- Caution patient or caregiver not to shake the vial or prefilled syringe of filgrastim because shaking may damage the filgrastim.
- Caution patient or caregiver not to use any filgrastim that is foamy, clouding, discolored, or contains particulate matter.
- Instruct patient to take exactly as prescribed and not to change or stop taking the dose unless advised by health care provider. Caution patient that taking too little filgrastim may not protect against infections, and taking too much may cause too many WBCs to be produced.
- Remind patient to rotate injection sites and never to inject into tissue that is tender, red, bruised, or hard, or has scars or stretch marks.
- Advise patient or caregiver that aching in the bones and muscles is the most common side effect, but can usually be relieved by taking non-aspirin pain reliever (eg, acetaminophen). Advise patient or caregiver to notify health care provider if bone or muscle aches are severe or are not relieved by acetaminophen.
- Instruct patient or caregiver to immediately notify health care provider if any of the following occur: signs or symptoms of infection (eg, fever, chills, rash, sore throat, diarrhea, or redness, swelling, or pain around a cut or open sore), pain in left upper stomach area or left shoulder tip area, rash, unexplained shortness of breath, wheezing, fast pulse, swelling around mouth or eyes.
- Advise patient or caregiver to notify health care provider if any of the following occur: persistent or recurrent nausea with or without vomiting, persistent or severe injection-site reactions (eg, redness, swelling, bruising, itching), any unexplained symptoms or feelings.
- Advise patient with sickle cell disease to drink plenty of fluids while using filgrastim and to report any signs of sickle cell crisis to health care provider.
Copyright © 2009 Wolters Kluwer Health.
More about filgrastim
- Other brands: Neupogen